Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG) - Concepedia

Concepedia

Publication | Closed Access

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

162

Citations

21

References

2015

Year

D. Mavroudis, Emmanouil Saloustros, N. Malamos, Stylianos Kakolyris, Ioannis Boukovinas, Pavlos Papakotoulas, Nikolaos Ziras, Vassilis Georgoulias

Annals of Oncology

Breast OncologyOncologyDose-dense ChemotherapyBreast CancerAdjuvant TrastuzumabCancer TreatmentMedicineRadiation OncologyHer2-positive Breast Cancer

References

	Year	Citations

Page 1